nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—Anorexia—Fluorouracil—pancreatic cancer	0.00156	0.00156	CcSEcCtD
Metolazone—Purpura—Doxorubicin—pancreatic cancer	0.00156	0.00156	CcSEcCtD
Metolazone—Insomnia—Irinotecan—pancreatic cancer	0.00155	0.00155	CcSEcCtD
Metolazone—Vomiting—Tamoxifen—pancreatic cancer	0.00154	0.00154	CcSEcCtD
Metolazone—Paraesthesia—Irinotecan—pancreatic cancer	0.00154	0.00154	CcSEcCtD
Metolazone—Lethargy—Doxorubicin—pancreatic cancer	0.00153	0.00153	CcSEcCtD
Metolazone—Hypersensitivity—Sunitinib—pancreatic cancer	0.00153	0.00153	CcSEcCtD
Metolazone—Rash—Tamoxifen—pancreatic cancer	0.00153	0.00153	CcSEcCtD
Metolazone—Dermatitis—Tamoxifen—pancreatic cancer	0.00153	0.00153	CcSEcCtD
Metolazone—Vomiting—Erlotinib—pancreatic cancer	0.00153	0.00153	CcSEcCtD
Metolazone—Somnolence—Irinotecan—pancreatic cancer	0.00152	0.00152	CcSEcCtD
Metolazone—Headache—Tamoxifen—pancreatic cancer	0.00152	0.00152	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00152	0.00152	CcSEcCtD
Metolazone—Rash—Erlotinib—pancreatic cancer	0.00151	0.00151	CcSEcCtD
Metolazone—Dermatitis—Erlotinib—pancreatic cancer	0.00151	0.00151	CcSEcCtD
Metolazone—Hyponatraemia—Doxorubicin—pancreatic cancer	0.00151	0.00151	CcSEcCtD
Metolazone—Insomnia—Gemcitabine—pancreatic cancer	0.00151	0.00151	CcSEcCtD
Metolazone—Dyspepsia—Irinotecan—pancreatic cancer	0.00151	0.00151	CcSEcCtD
Metolazone—Headache—Erlotinib—pancreatic cancer	0.0015	0.0015	CcSEcCtD
Metolazone—Paraesthesia—Gemcitabine—pancreatic cancer	0.0015	0.0015	CcSEcCtD
Metolazone—Chills—Docetaxel—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Metolazone—Asthenia—Sunitinib—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Metolazone—Dry skin—Epirubicin—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Metolazone—Decreased appetite—Irinotecan—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Metolazone—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.00148	0.00148	CcSEcCtD
Metolazone—Insomnia—Fluorouracil—pancreatic cancer	0.00148	0.00148	CcSEcCtD
Metolazone—Somnolence—Gemcitabine—pancreatic cancer	0.00148	0.00148	CcSEcCtD
Metolazone—Hypokalaemia—Epirubicin—pancreatic cancer	0.00148	0.00148	CcSEcCtD
Metolazone—Fatigue—Irinotecan—pancreatic cancer	0.00147	0.00147	CcSEcCtD
Metolazone—Paraesthesia—Fluorouracil—pancreatic cancer	0.00147	0.00147	CcSEcCtD
Metolazone—Pruritus—Sunitinib—pancreatic cancer	0.00147	0.00147	CcSEcCtD
Metolazone—Pain—Irinotecan—pancreatic cancer	0.00146	0.00146	CcSEcCtD
Metolazone—Constipation—Irinotecan—pancreatic cancer	0.00146	0.00146	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.00146	0.00146	CcSEcCtD
Metolazone—Somnolence—Fluorouracil—pancreatic cancer	0.00146	0.00146	CcSEcCtD
Metolazone—Decreased appetite—Gemcitabine—pancreatic cancer	0.00145	0.00145	CcSEcCtD
Metolazone—Dyspepsia—Fluorouracil—pancreatic cancer	0.00144	0.00144	CcSEcCtD
Metolazone—Nausea—Tamoxifen—pancreatic cancer	0.00144	0.00144	CcSEcCtD
Metolazone—Fatigue—Gemcitabine—pancreatic cancer	0.00144	0.00144	CcSEcCtD
Metolazone—Pain—Gemcitabine—pancreatic cancer	0.00143	0.00143	CcSEcCtD
Metolazone—Constipation—Gemcitabine—pancreatic cancer	0.00143	0.00143	CcSEcCtD
Metolazone—Nausea—Erlotinib—pancreatic cancer	0.00143	0.00143	CcSEcCtD
Metolazone—Decreased appetite—Fluorouracil—pancreatic cancer	0.00142	0.00142	CcSEcCtD
Metolazone—Diarrhoea—Sunitinib—pancreatic cancer	0.00142	0.00142	CcSEcCtD
Metolazone—Dysgeusia—Docetaxel—pancreatic cancer	0.00142	0.00142	CcSEcCtD
Metolazone—Abdominal distension—Epirubicin—pancreatic cancer	0.00141	0.00141	CcSEcCtD
Metolazone—Feeling abnormal—Irinotecan—pancreatic cancer	0.00141	0.00141	CcSEcCtD
Metolazone—Back pain—Docetaxel—pancreatic cancer	0.0014	0.0014	CcSEcCtD
Metolazone—Pain—Fluorouracil—pancreatic cancer	0.0014	0.0014	CcSEcCtD
Metolazone—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.0014	0.0014	CcSEcCtD
Metolazone—Muscle spasms—Docetaxel—pancreatic cancer	0.00139	0.00139	CcSEcCtD
Metolazone—Dry skin—Doxorubicin—pancreatic cancer	0.00138	0.00138	CcSEcCtD
Metolazone—Pancreatitis—Epirubicin—pancreatic cancer	0.00138	0.00138	CcSEcCtD
Metolazone—Dizziness—Sunitinib—pancreatic cancer	0.00137	0.00137	CcSEcCtD
Metolazone—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00137	0.00137	CcSEcCtD
Metolazone—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.00137	0.00137	CcSEcCtD
Metolazone—Hypokalaemia—Doxorubicin—pancreatic cancer	0.00137	0.00137	CcSEcCtD
Metolazone—Abdominal pain—Irinotecan—pancreatic cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Anaemia—Docetaxel—pancreatic cancer	0.00134	0.00134	CcSEcCtD
Metolazone—Vomiting—Sunitinib—pancreatic cancer	0.00132	0.00132	CcSEcCtD
Metolazone—Rash—Sunitinib—pancreatic cancer	0.00131	0.00131	CcSEcCtD
Metolazone—Dermatitis—Sunitinib—pancreatic cancer	0.00131	0.00131	CcSEcCtD
Metolazone—Abdominal distension—Doxorubicin—pancreatic cancer	0.00131	0.00131	CcSEcCtD
Metolazone—Urticaria—Fluorouracil—pancreatic cancer	0.0013	0.0013	CcSEcCtD
Metolazone—Headache—Sunitinib—pancreatic cancer	0.0013	0.0013	CcSEcCtD
Metolazone—Syncope—Docetaxel—pancreatic cancer	0.0013	0.0013	CcSEcCtD
Metolazone—Leukopenia—Docetaxel—pancreatic cancer	0.0013	0.0013	CcSEcCtD
Metolazone—Palpitations—Docetaxel—pancreatic cancer	0.00128	0.00128	CcSEcCtD
Metolazone—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.00128	0.00128	CcSEcCtD
Metolazone—Loss of consciousness—Docetaxel—pancreatic cancer	0.00127	0.00127	CcSEcCtD
Metolazone—Pancreatitis—Doxorubicin—pancreatic cancer	0.00127	0.00127	CcSEcCtD
Metolazone—Hyperglycaemia—Epirubicin—pancreatic cancer	0.00127	0.00127	CcSEcCtD
Metolazone—Cough—Docetaxel—pancreatic cancer	0.00126	0.00126	CcSEcCtD
Metolazone—Hypersensitivity—Irinotecan—pancreatic cancer	0.00126	0.00126	CcSEcCtD
Metolazone—Hypertension—Docetaxel—pancreatic cancer	0.00125	0.00125	CcSEcCtD
Metolazone—Drowsiness—Epirubicin—pancreatic cancer	0.00125	0.00125	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.00124	0.00124	CcSEcCtD
Metolazone—Chest pain—Docetaxel—pancreatic cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Arthralgia—Docetaxel—pancreatic cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Nausea—Sunitinib—pancreatic cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Asthenia—Irinotecan—pancreatic cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00121	0.00121	CcSEcCtD
Metolazone—Dry mouth—Docetaxel—pancreatic cancer	0.00121	0.00121	CcSEcCtD
Metolazone—Asthenia—Gemcitabine—pancreatic cancer	0.0012	0.0012	CcSEcCtD
Metolazone—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.00118	0.00118	CcSEcCtD
Metolazone—Epistaxis—Epirubicin—pancreatic cancer	0.00118	0.00118	CcSEcCtD
Metolazone—Pruritus—Gemcitabine—pancreatic cancer	0.00118	0.00118	CcSEcCtD
Metolazone—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.00117	0.00117	CcSEcCtD
Metolazone—Diarrhoea—Irinotecan—pancreatic cancer	0.00117	0.00117	CcSEcCtD
Metolazone—Agranulocytosis—Epirubicin—pancreatic cancer	0.00117	0.00117	CcSEcCtD
Metolazone—Shock—Docetaxel—pancreatic cancer	0.00116	0.00116	CcSEcCtD
Metolazone—Pruritus—Fluorouracil—pancreatic cancer	0.00116	0.00116	CcSEcCtD
Metolazone—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00116	0.00116	CcSEcCtD
Metolazone—Drowsiness—Doxorubicin—pancreatic cancer	0.00116	0.00116	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.00115	0.00115	CcSEcCtD
Metolazone—Diarrhoea—Gemcitabine—pancreatic cancer	0.00114	0.00114	CcSEcCtD
Metolazone—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.00113	0.00113	CcSEcCtD
Metolazone—Dizziness—Irinotecan—pancreatic cancer	0.00113	0.00113	CcSEcCtD
Metolazone—Anorexia—Docetaxel—pancreatic cancer	0.00113	0.00113	CcSEcCtD
Metolazone—Hepatitis—Epirubicin—pancreatic cancer	0.00112	0.00112	CcSEcCtD
Metolazone—Diarrhoea—Fluorouracil—pancreatic cancer	0.00112	0.00112	CcSEcCtD
Metolazone—Epistaxis—Doxorubicin—pancreatic cancer	0.00109	0.00109	CcSEcCtD
Metolazone—Vomiting—Irinotecan—pancreatic cancer	0.00109	0.00109	CcSEcCtD
Metolazone—Dizziness—Fluorouracil—pancreatic cancer	0.00108	0.00108	CcSEcCtD
Metolazone—Agranulocytosis—Doxorubicin—pancreatic cancer	0.00108	0.00108	CcSEcCtD
Metolazone—Rash—Irinotecan—pancreatic cancer	0.00108	0.00108	CcSEcCtD
Metolazone—Dermatitis—Irinotecan—pancreatic cancer	0.00108	0.00108	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.00108	0.00108	CcSEcCtD
Metolazone—Headache—Irinotecan—pancreatic cancer	0.00107	0.00107	CcSEcCtD
Metolazone—Insomnia—Docetaxel—pancreatic cancer	0.00107	0.00107	CcSEcCtD
Metolazone—Paraesthesia—Docetaxel—pancreatic cancer	0.00106	0.00106	CcSEcCtD
Metolazone—Erythema multiforme—Epirubicin—pancreatic cancer	0.00106	0.00106	CcSEcCtD
Metolazone—Vomiting—Gemcitabine—pancreatic cancer	0.00106	0.00106	CcSEcCtD
Metolazone—Somnolence—Docetaxel—pancreatic cancer	0.00105	0.00105	CcSEcCtD
Metolazone—Rash—Gemcitabine—pancreatic cancer	0.00105	0.00105	CcSEcCtD
Metolazone—Dermatitis—Gemcitabine—pancreatic cancer	0.00105	0.00105	CcSEcCtD
Metolazone—Tinnitus—Epirubicin—pancreatic cancer	0.00105	0.00105	CcSEcCtD
Metolazone—Headache—Gemcitabine—pancreatic cancer	0.00104	0.00104	CcSEcCtD
Metolazone—Vomiting—Fluorouracil—pancreatic cancer	0.00104	0.00104	CcSEcCtD
Metolazone—Dyspepsia—Docetaxel—pancreatic cancer	0.00104	0.00104	CcSEcCtD
Metolazone—Hepatitis—Doxorubicin—pancreatic cancer	0.00104	0.00104	CcSEcCtD
Metolazone—Rash—Fluorouracil—pancreatic cancer	0.00103	0.00103	CcSEcCtD
Metolazone—Dermatitis—Fluorouracil—pancreatic cancer	0.00103	0.00103	CcSEcCtD
Metolazone—Decreased appetite—Docetaxel—pancreatic cancer	0.00103	0.00103	CcSEcCtD
Metolazone—Headache—Fluorouracil—pancreatic cancer	0.00103	0.00103	CcSEcCtD
Metolazone—Fatigue—Docetaxel—pancreatic cancer	0.00102	0.00102	CcSEcCtD
Metolazone—Nausea—Irinotecan—pancreatic cancer	0.00102	0.00102	CcSEcCtD
Metolazone—Pain—Docetaxel—pancreatic cancer	0.00101	0.00101	CcSEcCtD
Metolazone—Constipation—Docetaxel—pancreatic cancer	0.00101	0.00101	CcSEcCtD
Metolazone—Chills—Epirubicin—pancreatic cancer	0.00101	0.00101	CcSEcCtD
Metolazone—Nausea—Gemcitabine—pancreatic cancer	0.00099	0.00099	CcSEcCtD
Metolazone—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000982	0.000982	CcSEcCtD
Metolazone—Feeling abnormal—Docetaxel—pancreatic cancer	0.000975	0.000975	CcSEcCtD
Metolazone—Nausea—Fluorouracil—pancreatic cancer	0.000973	0.000973	CcSEcCtD
Metolazone—Tinnitus—Doxorubicin—pancreatic cancer	0.000969	0.000969	CcSEcCtD
Metolazone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000967	0.000967	CcSEcCtD
Metolazone—Flatulence—Epirubicin—pancreatic cancer	0.000963	0.000963	CcSEcCtD
Metolazone—Tension—Epirubicin—pancreatic cancer	0.000959	0.000959	CcSEcCtD
Metolazone—Dysgeusia—Epirubicin—pancreatic cancer	0.000957	0.000957	CcSEcCtD
Metolazone—Nervousness—Epirubicin—pancreatic cancer	0.000949	0.000949	CcSEcCtD
Metolazone—Back pain—Epirubicin—pancreatic cancer	0.000945	0.000945	CcSEcCtD
Metolazone—Muscle spasms—Epirubicin—pancreatic cancer	0.00094	0.00094	CcSEcCtD
Metolazone—Abdominal pain—Docetaxel—pancreatic cancer	0.000935	0.000935	CcSEcCtD
Metolazone—Chills—Doxorubicin—pancreatic cancer	0.000932	0.000932	CcSEcCtD
Metolazone—Vision blurred—Epirubicin—pancreatic cancer	0.000921	0.000921	CcSEcCtD
Metolazone—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000907	0.000907	CcSEcCtD
Metolazone—Anaemia—Epirubicin—pancreatic cancer	0.000903	0.000903	CcSEcCtD
Metolazone—Agitation—Epirubicin—pancreatic cancer	0.000898	0.000898	CcSEcCtD
Metolazone—Flatulence—Doxorubicin—pancreatic cancer	0.000891	0.000891	CcSEcCtD
Metolazone—Tension—Doxorubicin—pancreatic cancer	0.000887	0.000887	CcSEcCtD
Metolazone—Dysgeusia—Doxorubicin—pancreatic cancer	0.000886	0.000886	CcSEcCtD
Metolazone—Malaise—Epirubicin—pancreatic cancer	0.000881	0.000881	CcSEcCtD
Metolazone—Nervousness—Doxorubicin—pancreatic cancer	0.000878	0.000878	CcSEcCtD
Metolazone—Vertigo—Epirubicin—pancreatic cancer	0.000878	0.000878	CcSEcCtD
Metolazone—Syncope—Epirubicin—pancreatic cancer	0.000876	0.000876	CcSEcCtD
Metolazone—Leukopenia—Epirubicin—pancreatic cancer	0.000875	0.000875	CcSEcCtD
Metolazone—Back pain—Doxorubicin—pancreatic cancer	0.000875	0.000875	CcSEcCtD
Metolazone—Hypersensitivity—Docetaxel—pancreatic cancer	0.000871	0.000871	CcSEcCtD
Metolazone—Muscle spasms—Doxorubicin—pancreatic cancer	0.000869	0.000869	CcSEcCtD
Metolazone—Palpitations—Epirubicin—pancreatic cancer	0.000864	0.000864	CcSEcCtD
Metolazone—Loss of consciousness—Epirubicin—pancreatic cancer	0.000859	0.000859	CcSEcCtD
Metolazone—Cough—Epirubicin—pancreatic cancer	0.000853	0.000853	CcSEcCtD
Metolazone—Vision blurred—Doxorubicin—pancreatic cancer	0.000852	0.000852	CcSEcCtD
Metolazone—Asthenia—Docetaxel—pancreatic cancer	0.000848	0.000848	CcSEcCtD
Metolazone—Hypertension—Epirubicin—pancreatic cancer	0.000844	0.000844	CcSEcCtD
Metolazone—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000839	0.000839	CcSEcCtD
Metolazone—Pruritus—Docetaxel—pancreatic cancer	0.000837	0.000837	CcSEcCtD
Metolazone—Anaemia—Doxorubicin—pancreatic cancer	0.000836	0.000836	CcSEcCtD
Metolazone—Chest pain—Epirubicin—pancreatic cancer	0.000832	0.000832	CcSEcCtD
Metolazone—Arthralgia—Epirubicin—pancreatic cancer	0.000832	0.000832	CcSEcCtD
Metolazone—Agitation—Doxorubicin—pancreatic cancer	0.000831	0.000831	CcSEcCtD
Metolazone—Anxiety—Epirubicin—pancreatic cancer	0.000829	0.000829	CcSEcCtD
Metolazone—Discomfort—Epirubicin—pancreatic cancer	0.000822	0.000822	CcSEcCtD
Metolazone—Malaise—Doxorubicin—pancreatic cancer	0.000816	0.000816	CcSEcCtD
Metolazone—Dry mouth—Epirubicin—pancreatic cancer	0.000814	0.000814	CcSEcCtD
Metolazone—Vertigo—Doxorubicin—pancreatic cancer	0.000812	0.000812	CcSEcCtD
Metolazone—Syncope—Doxorubicin—pancreatic cancer	0.000811	0.000811	CcSEcCtD
Metolazone—Leukopenia—Doxorubicin—pancreatic cancer	0.000809	0.000809	CcSEcCtD
Metolazone—Diarrhoea—Docetaxel—pancreatic cancer	0.000809	0.000809	CcSEcCtD
Metolazone—Palpitations—Doxorubicin—pancreatic cancer	0.000799	0.000799	CcSEcCtD
Metolazone—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000795	0.000795	CcSEcCtD
Metolazone—Cough—Doxorubicin—pancreatic cancer	0.000789	0.000789	CcSEcCtD
Metolazone—Shock—Epirubicin—pancreatic cancer	0.000785	0.000785	CcSEcCtD
Metolazone—Dizziness—Docetaxel—pancreatic cancer	0.000782	0.000782	CcSEcCtD
Metolazone—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000781	0.000781	CcSEcCtD
Metolazone—Hypertension—Doxorubicin—pancreatic cancer	0.000781	0.000781	CcSEcCtD
Metolazone—Chest pain—Doxorubicin—pancreatic cancer	0.00077	0.00077	CcSEcCtD
Metolazone—Arthralgia—Doxorubicin—pancreatic cancer	0.00077	0.00077	CcSEcCtD
Metolazone—Anxiety—Doxorubicin—pancreatic cancer	0.000767	0.000767	CcSEcCtD
Metolazone—Discomfort—Doxorubicin—pancreatic cancer	0.000761	0.000761	CcSEcCtD
Metolazone—Anorexia—Epirubicin—pancreatic cancer	0.00076	0.00076	CcSEcCtD
Metolazone—Dry mouth—Doxorubicin—pancreatic cancer	0.000753	0.000753	CcSEcCtD
Metolazone—Vomiting—Docetaxel—pancreatic cancer	0.000752	0.000752	CcSEcCtD
Metolazone—Rash—Docetaxel—pancreatic cancer	0.000746	0.000746	CcSEcCtD
Metolazone—Dermatitis—Docetaxel—pancreatic cancer	0.000745	0.000745	CcSEcCtD
Metolazone—Headache—Docetaxel—pancreatic cancer	0.000741	0.000741	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000727	0.000727	CcSEcCtD
Metolazone—Shock—Doxorubicin—pancreatic cancer	0.000726	0.000726	CcSEcCtD
Metolazone—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000723	0.000723	CcSEcCtD
Metolazone—Insomnia—Epirubicin—pancreatic cancer	0.000721	0.000721	CcSEcCtD
Metolazone—Paraesthesia—Epirubicin—pancreatic cancer	0.000716	0.000716	CcSEcCtD
Metolazone—Somnolence—Epirubicin—pancreatic cancer	0.000709	0.000709	CcSEcCtD
Metolazone—Anorexia—Doxorubicin—pancreatic cancer	0.000704	0.000704	CcSEcCtD
Metolazone—Nausea—Docetaxel—pancreatic cancer	0.000702	0.000702	CcSEcCtD
Metolazone—Dyspepsia—Epirubicin—pancreatic cancer	0.000702	0.000702	CcSEcCtD
Metolazone—Decreased appetite—Epirubicin—pancreatic cancer	0.000693	0.000693	CcSEcCtD
Metolazone—Fatigue—Epirubicin—pancreatic cancer	0.000688	0.000688	CcSEcCtD
Metolazone—Pain—Epirubicin—pancreatic cancer	0.000682	0.000682	CcSEcCtD
Metolazone—Constipation—Epirubicin—pancreatic cancer	0.000682	0.000682	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000672	0.000672	CcSEcCtD
Metolazone—Insomnia—Doxorubicin—pancreatic cancer	0.000668	0.000668	CcSEcCtD
Metolazone—Paraesthesia—Doxorubicin—pancreatic cancer	0.000663	0.000663	CcSEcCtD
Metolazone—Feeling abnormal—Epirubicin—pancreatic cancer	0.000657	0.000657	CcSEcCtD
Metolazone—Somnolence—Doxorubicin—pancreatic cancer	0.000656	0.000656	CcSEcCtD
Metolazone—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000652	0.000652	CcSEcCtD
Metolazone—Dyspepsia—Doxorubicin—pancreatic cancer	0.00065	0.00065	CcSEcCtD
Metolazone—Decreased appetite—Doxorubicin—pancreatic cancer	0.000642	0.000642	CcSEcCtD
Metolazone—Fatigue—Doxorubicin—pancreatic cancer	0.000636	0.000636	CcSEcCtD
Metolazone—Urticaria—Epirubicin—pancreatic cancer	0.000634	0.000634	CcSEcCtD
Metolazone—Constipation—Doxorubicin—pancreatic cancer	0.000631	0.000631	CcSEcCtD
Metolazone—Pain—Doxorubicin—pancreatic cancer	0.000631	0.000631	CcSEcCtD
Metolazone—Abdominal pain—Epirubicin—pancreatic cancer	0.000631	0.000631	CcSEcCtD
Metolazone—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000608	0.000608	CcSEcCtD
Metolazone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000604	0.000604	CcSEcCtD
Metolazone—Hypersensitivity—Epirubicin—pancreatic cancer	0.000588	0.000588	CcSEcCtD
Metolazone—Urticaria—Doxorubicin—pancreatic cancer	0.000586	0.000586	CcSEcCtD
Metolazone—Abdominal pain—Doxorubicin—pancreatic cancer	0.000583	0.000583	CcSEcCtD
Metolazone—Asthenia—Epirubicin—pancreatic cancer	0.000572	0.000572	CcSEcCtD
Metolazone—Pruritus—Epirubicin—pancreatic cancer	0.000564	0.000564	CcSEcCtD
Metolazone—Diarrhoea—Epirubicin—pancreatic cancer	0.000546	0.000546	CcSEcCtD
Metolazone—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000544	0.000544	CcSEcCtD
Metolazone—Asthenia—Doxorubicin—pancreatic cancer	0.00053	0.00053	CcSEcCtD
Metolazone—Dizziness—Epirubicin—pancreatic cancer	0.000527	0.000527	CcSEcCtD
Metolazone—Pruritus—Doxorubicin—pancreatic cancer	0.000522	0.000522	CcSEcCtD
Metolazone—Vomiting—Epirubicin—pancreatic cancer	0.000507	0.000507	CcSEcCtD
Metolazone—Diarrhoea—Doxorubicin—pancreatic cancer	0.000505	0.000505	CcSEcCtD
Metolazone—Rash—Epirubicin—pancreatic cancer	0.000503	0.000503	CcSEcCtD
Metolazone—Dermatitis—Epirubicin—pancreatic cancer	0.000502	0.000502	CcSEcCtD
Metolazone—Headache—Epirubicin—pancreatic cancer	0.0005	0.0005	CcSEcCtD
Metolazone—Dizziness—Doxorubicin—pancreatic cancer	0.000488	0.000488	CcSEcCtD
Metolazone—Nausea—Epirubicin—pancreatic cancer	0.000474	0.000474	CcSEcCtD
Metolazone—Vomiting—Doxorubicin—pancreatic cancer	0.000469	0.000469	CcSEcCtD
Metolazone—Rash—Doxorubicin—pancreatic cancer	0.000465	0.000465	CcSEcCtD
Metolazone—Dermatitis—Doxorubicin—pancreatic cancer	0.000465	0.000465	CcSEcCtD
Metolazone—Headache—Doxorubicin—pancreatic cancer	0.000462	0.000462	CcSEcCtD
Metolazone—Nausea—Doxorubicin—pancreatic cancer	0.000438	0.000438	CcSEcCtD
